GAMIDA CELL LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.017 USD | +2.41% |
|
-.--% | -95.88% |
| May. 23 | Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 10 | Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index | CI |
Financials (USD)
| Sales 2024 * | 16.79M | Sales 2025 * | - | Capitalization | 2.62M |
|---|---|---|---|---|---|
| Net income 2024 * | -71M | Net income 2025 * | - | EV / Sales 2024 * | 0.16 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.03
x | P/E ratio 2025 * |
-
| Employees | 147 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.41% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gamida Cell Ltd.
More recommendations
More press releases
| 1 day | +2.41% | ||
| 1 month | +9.68% | ||
| 3 months | -95.56% | ||
| 6 months | -94.85% | ||
| Current year | -95.88% |
1 month
0.01
0.02
Current year
0.010.49
1 year
0.012.51
3 years
0.016.84
5 years
0.0115.00
10 years
0.0115.41
| Managers | Title | Age | Since |
|---|---|---|---|
Mary Coelho
DFI | Director of Finance/CFO | 62 | 23-05-21 |
Ronit Simantov
CTO | Chief Tech/Sci/R&D Officer | 59 | 17-06-30 |
| Corporate Officer/Principal | - | 21-06-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 0.017 | +2.41% | 332,754 |
Delayed Quote OTC Markets, May 24, 2024 at 12:54 pm EDT
More quotes
Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The following are the Company's clinical pipeline products: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -95.88% | 2.62M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- GMDA Stock
